Business Description
Gentian Diagnostics AS
ISIN : NO0010748866
Compare
Compare
Traded in other countries / regions
GENT.Norway6FK.Germany IPO Date
2021-05-13Description
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic reagents (IVD) for use in medical diagnostics and research. Its portfolio and pipeline of reagents span areas of inflammations, severe infections, kidney diseases, heart failures, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP among others. Geographically, it generates a majority of its revenue from Europe followed by Asia and the United States of America.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.43 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | 0.97 | |||||
| Interest Coverage | 5.64 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 15.13 | |||||
| Beneish M-Score | -2.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 28.6 | |||||
| 3-Year EPS without NRI Growth Rate | 36.5 | |||||
| 3-Year Book Growth Rate | -9 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 25.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.77 | |||||
| 9-Day RSI | 24.11 | |||||
| 14-Day RSI | 28.54 | |||||
| 6-1 Month Momentum % | 38.79 | |||||
| 12-1 Month Momentum % | 33.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.73 | |||||
| Quick Ratio | 4.83 | |||||
| Cash Ratio | 3.74 | |||||
| Days Inventory | 202.39 | |||||
| Days Sales Outstanding | 50.17 | |||||
| Days Payable | 99.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 0.51 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.4 | |||||
| Operating Margin % | 1.71 | |||||
| Net Margin % | -1.36 | |||||
| FCF Margin % | 3.67 | |||||
| ROE % | -1.31 | |||||
| ROA % | -1.08 | |||||
| ROIC % | 3.5 | |||||
| 3-Year ROIIC % | 93.87 | |||||
| ROC (Joel Greenblatt) % | -2.3 | |||||
| ROCE % | -0.79 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 119.46 | |||||
| PS Ratio | 4.95 | |||||
| PB Ratio | 4.61 | |||||
| Price-to-Tangible-Book | 5.46 | |||||
| Price-to-Free-Cash-Flow | 130.92 | |||||
| Price-to-Operating-Cash-Flow | 56.76 | |||||
| EV-to-EBIT | -467.4 | |||||
| EV-to-EBITDA | 74.94 | |||||
| EV-to-Revenue | 4.06 | |||||
| EV-to-FCF | 119.52 | |||||
| Price-to-Net-Current-Asset-Value | 6.26 | |||||
| Price-to-Net-Cash | 14.15 | |||||
| Earnings Yield (Greenblatt) % | -0.21 | |||||
| FCF Yield % | 0.8 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gentian Diagnostics AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 12.836 | ||
| EPS (TTM) (€) | -0.012 | ||
| Beta | 0.76 | ||
| Volatility % | 31.71 | ||
| 14-Day RSI | 28.54 | ||
| 14-Day ATR (€) | 0.070979 | ||
| 20-Day SMA (€) | 4.223 | ||
| 12-1 Month Momentum % | 33.14 | ||
| 52-Week Range (€) | 2.99 - 5.05 | ||
| Shares Outstanding (Mil) | 15.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gentian Diagnostics AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gentian Diagnostics AS Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Gentian Diagnostics AS Frequently Asked Questions
What is Gentian Diagnostics AS(FRA:6FK)'s stock price today?
The current price of FRA:6FK is €3.82. The 52 week high of FRA:6FK is €5.05 and 52 week low is €2.99.
When is next earnings date of Gentian Diagnostics AS(FRA:6FK)?
The next earnings date of Gentian Diagnostics AS(FRA:6FK) is 2024-10-31.
Does Gentian Diagnostics AS(FRA:6FK) pay dividends? If so, how much?
Gentian Diagnostics AS(FRA:6FK) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers